H.R. 2296 · 116th Congress
FAIR Drug Pricing Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SchakowskySponsor8 cosponsors · 5 D, 3 R
1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
More Efficient Tools to Realize Information for Consumers Act or the METRIC Act This bill requires prescription drug manufacturers to report, and the Department of Health and Human Services (HHS) to publish, specified information related to prescription drug pricing and the pharmaceutical supply chain.
What it does: CRS summary · Reported to House · Sep 24, 2019
More Efficient Tools to Realize Information for Consumers Act or the METRIC Act
This bill requires prescription drug manufacturers to report, and the Department of Health and Human Services (HHS) to publish, specified information related to prescription drug pricing and the pharmaceutical supply chain. Specifically, HHS must publish reports submitted by drug manufacturers that include the percentage of any wholesale drug price increase that is greater than 10% in one calendar year (or 25% over three consecutive years), an explanation for the price increase, and other data. HHS must enter agreements with other agencies, research organizations, and public and private health insurers to share data submitted to HHS by drug manufacturers about the identity and quantity of drug sample requests by health practitioners.
HHS also must publish online aggregate data reported by pharmacy benefits managers (PBMs), including the percentage of prescriptions provided by mail-order, rate that generic versions of drugs are dispensed, and aggregate discounts, rebates, or price concessions negotiated.
The bill requires the Federal Trade Commission to report about potentially anticompetitive practices by PBMs such as steering patients to certain pharmacies or designing price formulas that increase the market share of higher priced drugs, among other information. The report also must include recommendations to increase transparency and deter anticompetitive behavior.
The bill further requires Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that provides prescribers with patient-specific formulary and benefit information. Additionally, the bill expands certain price reporting requirements for prescription drug payments under Medicare.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: More Efficient Tools to Realize Information for Consumers Act
Also known as: Fair Accountability and Innovative Research Drug Pricing Act of 2019
Latest action (Sep 24, 2019): Placed on the Union Calendar, Calendar No. 170.
Policy area: Health · Origin: House · Introduced: Apr 12, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.